Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.42 |
| ▸ | EHMT2 | Q96KQ7 | 7/20 | 0.41 |
| ▸ | EHMT1 | Q9H9B1 | 5/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3280907 | 0.90 | CYP2D6 (0.46) | CHEK1SRCEGFRKDR | |
| SCHEMBL6031477 | 0.74 | CHRNA7 (0.49) | — | |
| SCHEMBL6487213 | 0.72 | TSHR (0.46) | ABCB1EGFR | |
| SCHEMBL5912841 | 0.70 | TNFSF11 (0.44) | — | |
| SCHEMBL6881236 | 0.70 | PDE3B (0.45) | CHEK1EHMT2EHMT1TLR7TLR9 | |
| SCHEMBL4096057 | 0.67 | EGFR (0.53) | SRCEGFRFGFR1FLT1FLT4 | |
| SCHEMBL12448364 | 0.67 | KDM4E (0.51) | EHMT2EHMT1ABCB1 | |
| SCHEMBL5103081 | 0.67 | EHMT2 (0.50) | EHMT2EHMT1ABCB1 | |
| SCHEMBL30764769 | 0.67 | EHMT2 (0.50) | EHMT2EHMT1ABCB1 | |
| SCHEMBL199299 | 0.66 | EHMT2 (0.51) | EHMT2EHMT1TLR7TLR9SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044015-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044015-A1 | Quinazoline derivatives | NQO2, NRAS, TOP1 | CHEK1 823/4885EHMT2 3178/4885EHMT1 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.